The friction drops dramatically when prevention requires one appointment instead of daily discipline.
On a Monday in January 2026, Brazil's health regulator Anvisa approved Sunlenca — a twice-yearly injectable containing lenacapavir — as a near-total preventive barrier against HIV infection for people aged twelve and older. The decision marks a quiet but profound shift in how humanity might finally outpace a virus that has long exploited the fragility of daily habit. Where a pill demands discipline every morning, two injections a year ask only for presence twice — a small but revolutionary concession to the complexity of human life. The path to public access remains open but unfinished, dependent on pricing decisions and institutional will.
- A drug with near-100% efficacy against HIV has been approved in Brazil, raising urgent hopes for populations long underserved by prevention strategies that demand daily adherence.
- The approval disrupts the decades-old dominance of daily PrEP pills, introducing a capsid inhibitor so precise it blocks the virus at multiple stages of replication — a mechanism without precedent in HIV prevention.
- Sex workers, men who have sex with men, and others in high-transmission settings stand at the center of this moment, as the drug was designed with their risk profiles — and their realities — in mind.
- Despite the landmark approval, Sunlenca cannot yet reach public health patients: pricing must be set by a regulatory chamber, and a national commission must still decide whether it belongs in Brazil's public formulary.
- The WHO's prior endorsement of lenacapavir as the closest existing alternative to an HIV vaccine lends the Brazilian decision global weight, signaling a potential turning point in prevention strategy worldwide.
Brazil's National Health Surveillance Agency, Anvisa, approved Sunlenca on Monday — an injectable medication containing lenacapavir that needs to be administered only twice a year and has demonstrated near-total efficacy in preventing HIV infection. The drug is authorized for people over twelve who weigh at least thirty-five kilograms and face genuine exposure risk, including sex workers, men who have sex with men, and others in high-transmission environments.
What makes Sunlenca remarkable is both its mechanism and its simplicity. Lenacapavir is a first-in-class capsid inhibitor — it targets the protein shell protecting the virus's genetic material, disrupting HIV-1 replication at multiple stages of its life cycle. Where the current standard, daily PrEP pills, demands consistent discipline that life often makes impossible, two injections a year remove that burden almost entirely. The World Health Organization recognized this potential last year, calling the approach the best available alternative to an HIV vaccine.
Yet the approval is only the opening move. Before Sunlenca can reach patients through Brazil's public health system, the SUS, two additional processes must unfold: a regulatory chamber must establish a maximum price, and a national commission must evaluate whether the drug belongs in the public formulary. The Ministry of Health holds the final decision. These steps are not procedural formalities — they are the mechanisms that determine whether a scientific breakthrough translates into actual access for the people most at risk.
Sunlenca fits into a broader philosophy of combined HIV prevention — layered tools addressing different populations and moments of vulnerability. Its approval removes one of the most persistent obstacles in that framework: the daily discipline a pill requires. Whether it becomes a genuine turning point or remains a private-market innovation depends entirely on what happens next, in the slower, less celebrated corridors of pricing and policy.
Brazil's health regulator gave the green light on Monday to an injection that arrives twice a year and promises to prevent HIV infection with near-total effectiveness. The drug is called Sunlenca, and it contains lenacapavir, a compound that works by blocking multiple stages of how the HIV-1 virus replicates inside the body. It's meant for people over twelve years old who weigh at least thirty-five kilograms and face genuine risk of infection—a category that includes sex workers, men who have sex with men, and others in high-transmission settings.
The approval from Anvisa, Brazil's National Health Surveillance Agency, marks a significant shift in how the country can approach HIV prevention. Until now, the main preventive strategy available has been PrEP—pre-exposure prophylaxis—which typically means taking a daily pill. Adherence to daily medication is hard. People forget. Life gets messy. Sunlenca sidesteps that problem by requiring just two injections per year, spaced six months apart. The drug can also be taken as an oral tablet during the initial phase of treatment, but the injection is where the innovation lies.
The mechanism is elegant in its specificity. Lenacapavir is a first-in-class capsid inhibitor, meaning it targets the protein shell that protects the virus's genetic material. By disrupting how that shell functions, the drug prevents the virus from replicating at multiple stages of its life cycle. Clinical trials have shown efficacy rates approaching one hundred percent—a figure that, in the context of HIV prevention, is extraordinary. The World Health Organization endorsed this approach last year as the closest thing to an HIV vaccine we currently have, a recognition of how transformative the drug could be for prevention strategies globally.
But approval from Anvisa is only the first step. Before Sunlenca reaches patients through Brazil's public health system—the SUS—two more hurdles must be cleared. The Medicines Market Regulation Chamber must set a maximum price, and then the National Commission for Incorporation of Technologies into the Unified Health System must evaluate whether the drug should be added to the public formulary. The Ministry of Health will make the final call. These are not formalities; they determine whether a breakthrough treatment becomes accessible to the people who need it most, or remains available only to those who can afford it privately.
The approval arrives as part of a broader shift in HIV prevention thinking. Sunlenca fits into what public health officials call "combined prevention"—a layered approach that includes regular testing, condom use, antiretroviral treatment for those already infected, post-exposure prophylaxis for emergencies, and specialized care for pregnant people living with HIV. Each tool addresses a different moment or population. What Sunlenca does is remove one of the biggest barriers to prevention: the daily discipline required to take a pill. For a disease that has killed millions and continues to spread, particularly among marginalized populations, that matters enormously.
The question now is timing and access. How quickly will pricing be set? Will the cost be reasonable enough for the SUS to absorb it? Will it reach the people in the highest-risk groups, or will it become another treatment available mainly to the wealthy? These questions will determine whether Monday's approval becomes a genuine turning point in Brazil's fight against HIV, or simply another innovation that exists on paper while the virus continues its work.
Notable Quotes
The approval makes Sunlenca a new tool to reduce HIV-1 transmission risk, offering a semi-annual regimen that improves adherence and reduces burden on health systems.— Anvisa
The Hearth Conversation Another angle on the story
Why does it matter that this is an injection instead of a daily pill?
Because people are human. A daily pill requires discipline every single day, forever. You miss one, you're vulnerable. With an injection twice a year, you show up to a clinic, get the shot, and you're protected for six months. The friction drops dramatically.
But doesn't that mean you have to remember to go back in six months?
Yes, but that's a single appointment, not three hundred and sixty-five decisions. It's the difference between a habit you have to maintain and a procedure you schedule. For people whose lives are chaotic—unstable housing, work that doesn't allow time off—that difference is enormous.
The article mentions it still needs pricing approval. What does that actually mean?
It means the government hasn't decided how much it will cost or whether the public health system can afford to buy it. A drug can be safe and effective and still be too expensive for a country to distribute widely. That's the real test now.
Who benefits most from this?
People at highest risk of infection—sex workers, men who have sex with men, transgender people, people in relationships where one partner is HIV-positive. Anyone for whom prevention is urgent but daily pills have failed them before.
The WHO called this the closest thing to an HIV vaccine. Why is that comparison important?
Because an HIV vaccine has been the holy grail for forty years and we still don't have one. This drug does what a vaccine would do—it prevents infection—without requiring the immune system to do the work. It's a practical substitute for something we've been chasing since the eighties.